CPT CODE J3489, J9310, J9201 - Medical Billing and Coding - Procedure code, ICD CODE. Zoledronic acid is indicated for the treatment of:
T50.4X5A is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Short description: Adverse effect of drugs affecting uric acid metabolism, init. The 2018/2019 edition of ICD-10-CM T50.4X5A became effective on October 1, 2018.
Zoledronic acid is indicated for the treatment of: Bone metastases from solid tumors in conjunction with standard antineoplastic therapy, including bone metastases from multiple myeloma, breast carcinoma, prostate carcinoma, and other solid tumors. Note: Prostate cancer should have progressed after treatment with at least one hormonal therapy;
Encounter for antineoplastic immunotherapy. Z51.12 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2020 edition of ICD-10-CM Z51.12 became effective on October 1, 2019. This is the American ICD-10-CM version of Z51.12 - other international versions of ICD-10 Z51.12 may differ.
Group 5CodeDescriptionJ3489Zoledronic acid 1mg
HCPCS code J3489 (Injection, zoledronic acid, 1 mg) should be used to report Zometa®). The number of units billed on a claim should be 4 since Zometa is given as a single 4 mg injection for the indications outlined in the LCD.
Zoledronic acid (ZOL) is an intravenous bisphosphonate that is given once yearly for the treatment of osteoporosis via a medically supervised 15-minute infusion. This ensures compliance for a full 12 months.
Injectable Drugs Coverage Medicare Part A or Medicare Part B will pay for a portion of the cost of osteoporosis medications delivered intravenously or by injection. These medications may include ibandronate (Boniva), zoledronic acid (Reclast), denosumab (Prolia) and sometimes calcitonin (Miacalcin).
0 – Age-Related Osteoporosis without Current Pathological Fracture. ICD-Code M81. 0 is a billable ICD-10 code used for healthcare diagnosis reimbursement of Age-Related Osteoporosis without Current Pathological Fracture.
The appropriate HCPCS Level II supply code for Reclast® is J3489 Injection, zoledronic acid, 1 mg. For an initial infusion of Reclast® lasting 16 minutes or longer, report 96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour.
Reclast and Zometa are two different brands of zoledronic acid. Reclast is used to treat or prevent osteoporosis caused by menopause, or steroid use. This medicine also increases bone mass in men with osteoporosis. Reclast is for use when you have a high risk of bone fracture.
For bone cancer and multiple myeloma, this medicine is usually given every 3 to 4 weeks. This treatment will continue until your body responds to the medicine. For osteoporosis, this medicine is usually given once a year and will continue until your body responds to the medicine.
The usual dose is 5 mg given as one infusion per year into a vein by your doctor or nurse. The infusion will take at least 15 minutes. In case you recently broke your hip, it is recommended that Zoledronic acid 5 mg is administered two or more weeks after your hip repair surgery.
As with all medications, the cost of zoledronic acid can vary. Factors that may affect the price you'll pay include your treatment plan and your insurance coverage. It may also depend on the cost of the visit to a healthcare professional to receive doses of zoledronic acid.
The code 96365 is used to code for the 20-minute Reclast infusion. For the infusions to be considered as an initial hour, the infusion has to be at least 16 minutes long.
Do Medicare prescription drug plans cover Reclast? No. In general, Medicare prescription drug plans (Part D) do not cover this drug.
CPT® Code 96365 in section: Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug)
Intravenous (IV) infusions are billed based upon the CPT®/HCPCS description of the service rendered. A provider may bill for the total time of the infusion using the appropriate add-on codes (i.e. the CPT®/HCPCS for each additional unit of time) if the times are documented.
Do Medicare prescription drug plans cover Reclast? No. In general, Medicare prescription drug plans (Part D) do not cover this drug.
The average retail price for Reclast is $1,318.15 for 1, 100ML of 5MG/100ML Solution of Reclast. Ask the clinic or hospital where you receive your Reclast infusion if they will accept a SingleCare Reclast coupon; you could pay only $53.21 for 1, 100ML of 5MG/100ML Bottle of generic Reclast.
Use secondary code (s) from Chapter 20, External causes of morbidity, to indicate cause of injury. Codes within the T section that include the external cause do not require an additional external cause code. Type 1 Excludes.
The 2022 edition of ICD-10-CM T50.4X5A became effective on October 1, 2021.
Zoledronic acid is indicated for the treatment of: Bone metastases from solid tumors in conjunction with standard antineoplastic therapy , including bone metastases from multiple myeloma, breast carcinoma, prostate carcinoma, and other solid tumors.
C88.2 – C91.62 – Opens in a new window Heavy chain disease – Prolymphocytic leukemia of T-cell type, in relapse
C38.8 Malignant neoplasm of overlapping sites of heart, mediastinum and pleura
Intravenous administration by infusion should be billed with procedure code 96365 for first hour and procedure code 96366 for each additional hour. If the administration is by IV push, use procedure code 96374.
To report low bone mass for procedure code J3489 use diagnosis code M81.0 - Age-related osteoporosis without current pathological fracture. For codes in the table below that require a 7th character, letter A initial encounter for fracture, D subsequent encounter for fracture with routine healing, G subsequent encounter for fracture with delayed healing, K for subsequent encounter for fracture with nonunion, P for subsequent encounter for fracture with malunion, or S sequela may be used.
The appropriate HCPCS Level II supply code for Reclast® is J3489 Injection, zoledronic acid, 1 mg.
Billing for hydration in combination with other infusions is a common source of confusion. Hydration of 30 minutes or less is never separately billable. Nor may you separately report hydration if it’s performed concurrently with administration of a drug.
An unlabeled use of a drug is a use that is not included as an indication on the drug's label as approved by the FDA. FDA approved drugs used for indications other than what is indicated on the official label may be covered under Medicare if the contractor determines the use to be medically accepted, taking into consideration the major drug compendia, authoritative medical literature and/or accepted standards of medical practice. The following guidelines identify three categories in which medications would not be reasonable and necessary according to accepted standards of medical practice.
Injection Method Not Indicated – – Medication given by injection (parenterally) is not covered if standard medical practice indicates that the administration of the medication by mouth (orally) is effective and is an accepted or preferred method of administration.